Kestra Advisory Services’s Avadel Pharmaceuticals AVDL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $106K | Hold |
12,000
| – | – | ﹤0.01% | 2725 |
|
|
2025
Q1 | $94K | Sell |
12,000
-5,600
| -32% | -$43.8K | ﹤0.01% | 2596 |
|
|
2024
Q4 | $185K | Buy |
17,600
+1,100
| +7% | +$11.6K | ﹤0.01% | 2494 |
|
|
2024
Q3 | $216K | Buy |
16,500
+400
| +2% | +$5.25K | ﹤0.01% | 2316 |
|
|
2024
Q2 | $226K | Hold |
16,100
| – | – | ﹤0.01% | 2309 |
|
|
2024
Q1 | $272K | Sell |
16,100
-7,050
| -30% | -$119K | ﹤0.01% | 2071 |
|
|
2023
Q4 | $327K | Buy |
23,150
+1,200
| +5% | +$16.9K | ﹤0.01% | 1793 |
|
|
2023
Q3 | $226K | Buy |
21,950
+1,500
| +7% | +$15.5K | ﹤0.01% | 1858 |
|
|
2023
Q2 | $337K | Buy |
20,450
+6,450
| +46% | +$106K | ﹤0.01% | 1539 |
|
|
2023
Q1 | $128K | Sell |
14,000
-1,650
| -11% | -$15.1K | ﹤0.01% | 1924 |
|
|
2022
Q4 | $112K | Sell |
15,650
-31,250
| -67% | -$224K | ﹤0.01% | 2131 |
|
|
2022
Q3 | $235K | Buy |
46,900
+16,500
| +54% | +$82.7K | ﹤0.01% | 1756 |
|
|
2022
Q2 | $74K | Sell |
30,400
-16,150
| -35% | -$39.3K | ﹤0.01% | 2012 |
|
|
2022
Q1 | $318K | Buy |
46,550
+12,900
| +38% | +$88.1K | ﹤0.01% | 1556 |
|
|
2021
Q4 | $272K | Buy |
33,650
+23,650
| +237% | +$191K | ﹤0.01% | 1656 |
|
|
2021
Q3 | $98K | Hold |
10,000
| – | – | ﹤0.01% | 2057 |
|
|
2021
Q2 | $67K | Hold |
10,000
| – | – | ﹤0.01% | 1965 |
|
|
2021
Q1 | $90K | Sell |
10,000
-17
| -0.2% | -$153 | ﹤0.01% | 1809 |
|
|
2020
Q4 | $67K | Buy |
10,017
+17
| +0.2% | +$114 | ﹤0.01% | 1807 |
|
|
2020
Q3 | $50K | Buy |
+10,000
| New | +$50K | ﹤0.01% | 1385 |
|